Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Aim: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Saad Z Usmani
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Becaris Publishing Limited 2023-04-01
Serie:	Journal of Comparative Effectiveness Research
Soggetti:	b-cell maturation antigen bispecific antibody comparative effectiveness indirect treatment comparison majestec-1
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!